New product introductions offset slightly weaker Q4 results due to COVID-19 headwinds and international pressure.
While the Trauma segment was not impacted as heavily due to COVID-19 headwinds, companies that play within the space were impacted by deferrals of elective surgeries such as limb restoration. Long bone trauma volumes remained healthy as players cited new product introductions as growth drivers for the segment.
Among the many topics covered in detail in our comprehensive Q421/FY21 Trauma Market Recap* are:
- Complete Q421/FY21 Trauma Market Overview
- SmartTRAK's Expert Analysis and Insights
- All Market News including Revenues, Data, Charts and Shares
- New Products Help Offset Weaker Q4 Results
- Q421 Regulatory Highlights
DePuy Synthes* Trauma business was impacted globally by competitive pressure in China. However, continued market stabilization and recent product launches helped offset the competitive headwinds resulting in WW growth in Q421. For 2021, Trauma revenue improved +10.4% over 2020 in the US and OUS. The Company cited new products such as ...
*The entire unedited article can only be viewed by SmartTRAK subscribers to this module. For more information on SmartTRAK, including how to receive a demo and subscribe, please click the button below.
SmartTRAK is the leading source of competitive intelligence used by the top ten global orthopedic and wound care companies. If you would like a demo of what SmartTRAK has to offer and how we can help increase proficiency, improve productivity and reduce costs for your company, just click here.
